{
    "clinical_study": {
        "@rank": "25173", 
        "arm_group": [
            {
                "arm_group_label": "Liraglutide alone", 
                "arm_group_type": "Active Comparator", 
                "description": "Liraglutide 1.8mg once daily subcutaneous injection"
            }, 
            {
                "arm_group_label": "Endobarrier alone", 
                "arm_group_type": "Experimental", 
                "description": "Duodenal-jejunal bypass liner (Endobarrier) device implantation without additional GLP-1RA therapy"
            }, 
            {
                "arm_group_label": "Endobarrier and Liraglutide", 
                "arm_group_type": "Experimental", 
                "description": "Duodenal-jejunal bypass liner (Endobarrier) device with combined liraglutide 1.2mg once daily subcutaneous injection"
            }
        ], 
        "brief_summary": {
            "textblock": "New effective non-surgical treatments are needed for patients whose obesity and type 2\n      diabetes (T2DM) do not respond to current medical therapies. We propose a randomised\n      controlled trial of Endobarrier, an implantable intestinal device that separates ingested\n      food from contacting the first 60cm of intestine where sited and that mimics some of the\n      clinical effects of bariatric surgery (improved metabolic control with weight loss)  with or\n      without continued use of the GLP-1 receptor agonist (GLP-1RA) Liraglutide 1.2mg vs\n      Liraglutide 1.8mg without the device in obese patients with T2DM who remain with suboptimal\n      glycaemic control despite current conventional diabetes treatment, in an NHS setting.\n\n      Seventy-two patients with T2DM and obesity (HbA1c\u22657.5%, BMI\u226535kg/m2) despite previous\n      GLP-1RA therapy will be studied over 24 months and randomised to receive Endobarrier with\n      continued Liraglutide 1.2mg for 12 months; Endobarrier alone for 12 months; or Liraglutide\n      1.8mg without Endobarrier.\n\n      We will investigate potential mechanisms of action and their time course as part of the\n      study by repeated measures of: 1. insulin resistance measures, gut peptides, bile acids; 2.\n      energy intake and nutritional composition; 3. liver fat stores, 4. intestinal inflammation\n      and permeability measures.\n\n      The data will inform clinical use of the device and development of new treatments for T2DM\n      and obesity."
        }, 
        "brief_title": "Randomisation to Endobarrier Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity)", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Type 2 Diabetes", 
            "Obesity", 
            "Diabesity"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Obesity"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  type 2 diabetes with latest HbA1c \u22657.5% (\u226558mmol/mol)\n\n          -  obesity with latest BMI \u226535 Kg/m2 (\u226530 Kg/m2 for those of South Asian origin)\n\n          -  liraglutide therapy for at least 6 months - HbA1c and weight trend data should be\n             available\n\n          -  stable weight and HbA1c in preceding 3 months (<3 Kg reduction in weight and <0.3%\n             reduction in HbA1c)\n\n        Exclusion Criteria:\n\n          -  <18 years of age\n\n          -  abnormal intestinal anatomy e.g. Crohn's disease\n\n          -  contraindication to oesophago-gastroduodenoscopy\n\n          -  previous bariatric surgery or bowel surgery\n\n          -  active infection\n\n          -  anticoagulation therapy which cannot be discontinued/ coagulopathy INR >1.3\n\n          -  eGFR <30\n\n          -  known portal hypertension\n\n          -  previous pancreatitis or amylase > 3 times the upper limit of normal\n\n          -  uncontrolled cardiovascular disease\n\n          -  lactating or pregnant females\n\n          -  patients taking aspirin in whom it should continue (e.g. active ischaemic heart\n             disease or cerebrovascular disease)\n\n          -  excess anaesthetic risk as identified by the anaesthetist or investigator (e.g.\n             uncontrolled obstructive sleep apnoea)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "72", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02055014", 
            "org_study_id": "12DIAB15", 
            "secondary_id": [
                "ISRCTN00151053", 
                "2012-004988-42"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Liraglutide alone", 
                    "Endobarrier and Liraglutide"
                ], 
                "intervention_name": "Liraglutide", 
                "intervention_type": "Drug", 
                "other_name": "Victoza"
            }, 
            {
                "arm_group_label": [
                    "Endobarrier alone", 
                    "Endobarrier and Liraglutide"
                ], 
                "intervention_name": "Duodenal-jejunal bypass liner - Endobarrier device", 
                "intervention_type": "Device", 
                "other_name": "EC Certificate Full Quality Assurance System: Certificate US08/5323"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glucagon-Like Peptide 1", 
                "Incretins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Endobarrier", 
            "Duodenal-jejunal bypass liner", 
            "Glucagon-like peptide-1 receptor agonist", 
            "Liraglutide", 
            "Diabesity", 
            "Type 2 diabetes", 
            "Obesity"
        ], 
        "lastchanged_date": "February 3, 2014", 
        "link": {
            "description": "REVISE-Diabesity website", 
            "url": "http://www.diabetologists-abcd.org.uk/Research/endobarrier_study.htm"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United Kingdom", 
                        "zip": "B18 7QH"
                    }, 
                    "name": "Department of Diabetes, City Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Bob Ryder, MD FRCP", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Piya Sen Gupta, BMedSci MRCP", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Glasgow", 
                        "country": "United Kingdom", 
                        "zip": "G0"
                    }, 
                    "name": "Glasgow Royal Infirmary"
                }, 
                "investigator": {
                    "last_name": "Russell Drummond, MD FRCP", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "SE5 9RS"
                    }, 
                    "name": "Diabetes Research Group, King's College London"
                }, 
                "investigator": [
                    {
                        "last_name": "Stephanie A Amiel, BSc MD FRCP", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Piya Sen Gupta, BMedSci MRCP", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "SE1"
                    }, 
                    "name": "Department of Diabetes, Guy's and St Thomas' Hospitals"
                }, 
                "investigator": [
                    {
                        "last_name": "Barbara McGowan, MA MRCP PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Piya Sen Gupta, BMedSci MRCP", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "3", 
        "official_title": "Randomisation to Endoluminal Intestinal Liner Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity)", 
        "overall_contact": {
            "email": "piya.sengupta@nhs.net", 
            "last_name": "Piya Sen Gupta, BMedSci MRCP", 
            "phone": "+442032991851", 
            "phone_ext": "1970"
        }, 
        "overall_official": {
            "affiliation": "Sandwell and West Birmingham Hospitals NHS Trust", 
            "last_name": "Bob Ryder, MD FRCP", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United Kingdom: Research Ethics Committee", 
                "United Kingdom: National Institute for Health Research"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "HbA1c (mmol/mol; %) at end of follow-up period compared to baseline. This will be 12 months following Endobarrier device removal which will usually be 24 months after initial the device has first been implanted (for 12 months) or 24 months from Liraglutide 1.8mg initiation.", 
            "measure": "Glycated haemoglobin (HbA1c)", 
            "safety_issue": "No", 
            "time_frame": "24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02055014"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sandwell & West Birmingham Hospitals NHS Trust", 
            "investigator_full_name": "Dr Bob Ryder", 
            "investigator_title": "Chief Investigator, Consultant Physician (Diabetes)", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Weight (Kg) measured at end of follow-up period compared to baseline. This will be 12 months following Endobarrier device removal which will usually be 24 months after the device has first been implanted (for 12 months) or 24 months from Liraglutide 1.8mg initiation.", 
            "measure": "Weight", 
            "safety_issue": "No", 
            "time_frame": "24 months"
        }, 
        "source": "Sandwell & West Birmingham Hospitals NHS Trust", 
        "sponsors": {
            "collaborator": {
                "agency": "Association of British Clinical Diabetologists", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Sandwell & West Birmingham Hospitals NHS Trust", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}